AbbVie : ABBV

All AbbVie Articles

622 Articles

John Seetoo | May 29, 2026 at 10:01 AM EDT

VYM Climbs 26% In a Year While Its Core Dividend Payers Extend Their Streaks

The Vanguard High Dividend Yield Index Fund ETF Shares (NYSEARCA:VYM) is one of the simplest income vehicles in the market:…

John Seetoo | May 28, 2026 at 11:44 AM EDT

SCHD’s $71.6 Billion Portfolio Delivers 20% Gains Plus 3.3% Yield This Year

Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has become one of the most-owned dividend funds in the country, with $71.6 billion…

Omor Ibne Ehsan | May 26, 2026 at 9:50 AM EDT

SCHD’s Dividend Quality Filter Now Concentrates Over 40 Percent of Your Money in Just Ten Stocks

Most investors buy Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) because the fund's reputation tells them they are buying diversification. SCHD…

Vandita Jadeja | May 25, 2026 at 7:47 AM EDT

Two Paths to Growth: Johnson & Johnson vs AbbVie

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that beat revenue expectations…

Joel South | May 23, 2026 at 8:41 AM EDT

The Dividend Stocks That Generate $60,000 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)

Holding a high-yield dividend portfolio in a taxable account at the 24% federal bracket means writing the IRS a $14,400…

Joel South | May 22, 2026 at 7:36 AM EDT

The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You

Replacing a real paycheck with dividends is the cleanest version of financial independence. The income target here is $65,000 per…

Michael Williams | May 21, 2026 at 7:30 AM EDT

Why retirees are banking on SCHD’s 15-year unbroken dividend streak

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has built its reputation on paying reliable, growing quarterly distributions to income investors,…

Omor Ibne Ehsan | May 19, 2026 at 4:19 PM EDT

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by…

Alex Sirois | May 15, 2026 at 11:40 AM EDT

Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now

Realty Income (NYSE:O | O Price Prediction) is dominating dividend feeds on Reddit and X again, with monthly-payer loyalists pointing…

Austin Smith | May 7, 2026 at 5:24 PM EDT

Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain

Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’…

Vandita Jadeja | May 6, 2026 at 10:32 AM EDT

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest…

Vandita Jadeja | May 4, 2026 at 8:55 AM EDT

10 Years, Zero Regrets: The Dividend Stocks I Keep Buying

Dividend stocks can be a pillar for long-term investing, generating passive income and offering stability even during tough environments. The…

Vandita Jadeja | Apr 30, 2026 at 10:40 AM EDT

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Our AbbVie (NYSE:ABBV | ABBV Price Prediction) call lands on the constructive side of the ledger after a noisy but…

Lee Jackson | Apr 30, 2026 at 7:49 AM EDT

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading session that saw all major indices…

John Seetoo | Apr 25, 2026 at 6:35 AM EDT

Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital

Income investors shopping the healthcare aisle often land on Gabelli Healthcare & WellnessRx Trust (NYSE:GRX), a closed-end fund managed by…

1 2 3 4 5 6 … 42

AbbVie : ABBV

All AbbVie Articles

VYM Climbs 26% In a Year While Its Core Dividend Payers Extend Their Streaks

SCHD’s $71.6 Billion Portfolio Delivers 20% Gains Plus 3.3% Yield This Year

SCHD’s Dividend Quality Filter Now Concentrates Over 40 Percent of Your Money in Just Ten Stocks

Two Paths to Growth: Johnson & Johnson vs AbbVie

The Dividend Stocks That Generate $60,000 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)

The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You

Why retirees are banking on SCHD’s 15-year unbroken dividend streak

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now

Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

10 Years, Zero Regrets: The Dividend Stocks I Keep Buying

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital

Math Doesn’t Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

Math Doesn't Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

Math Doesn’t Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

AbbVie : ABBV

All AbbVie Articles

VYM Climbs 26% In a Year While Its Core Dividend Payers Extend Their Streaks

SCHD’s $71.6 Billion Portfolio Delivers 20% Gains Plus 3.3% Yield This Year

SCHD’s Dividend Quality Filter Now Concentrates Over 40 Percent of Your Money in Just Ten Stocks

Two Paths to Growth: Johnson & Johnson vs AbbVie

The Dividend Stocks That Generate $60,000 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)

The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You

Why retirees are banking on SCHD’s 15-year unbroken dividend streak

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now

Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

10 Years, Zero Regrets: The Dividend Stocks I Keep Buying

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital

Math Doesn’t Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

Featured Reads

Math Doesn't Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62